CN113015722A - 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型 - Google Patents

一种低氧诱导因子脯氨酰羟化酶抑制剂晶型 Download PDF

Info

Publication number
CN113015722A
CN113015722A CN202080004385.2A CN202080004385A CN113015722A CN 113015722 A CN113015722 A CN 113015722A CN 202080004385 A CN202080004385 A CN 202080004385A CN 113015722 A CN113015722 A CN 113015722A
Authority
CN
China
Prior art keywords
crystal form
csi
form csi
compound
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080004385.2A
Other languages
English (en)
Other versions
CN113015722B (zh
Inventor
陈敏华
吴克林
史佳明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmaceutical Suzhou Co Ltd
Original Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmaceutical Suzhou Co Ltd filed Critical Crystal Pharmaceutical Suzhou Co Ltd
Priority to CN202210068909.5A priority Critical patent/CN114344301B/zh
Publication of CN113015722A publication Critical patent/CN113015722A/zh
Application granted granted Critical
Publication of CN113015722B publication Critical patent/CN113015722B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

化合物I的新晶型及其制备方法，含有该晶型的药物组合物，以及该晶型在制备低氧诱导因子脯氨酰羟化酶抑制剂药物和治疗受低氧诱导因子介导的病症药物中的用途。化合物I晶型比现有技术具有一种或多种改进的性质，对未来该药物的优化和开发具有重要价值。
Figure DDA0003048112970000011

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN202080004385.2A 2019-10-22 2020-09-28 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型 Active CN113015722B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210068909.5A CN114344301B (zh) 2019-10-22 2020-09-28 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2019110072352 2019-10-22
CN201911007235 2019-10-22
CN202010057113 2020-01-17
CN2020100571130 2020-01-17
CN2020101982756 2020-03-19
CN202010198275 2020-03-19
PCT/CN2020/118386 WO2021077994A1 (zh) 2019-10-22 2020-09-28 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210068909.5A Division CN114344301B (zh) 2019-10-22 2020-09-28 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型

Publications (2)

Publication Number Publication Date
CN113015722A true CN113015722A (zh) 2021-06-22
CN113015722B CN113015722B (zh) 2022-02-11

Family

ID=75619679

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210068909.5A Active CN114344301B (zh) 2019-10-22 2020-09-28 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型
CN202080004385.2A Active CN113015722B (zh) 2019-10-22 2020-09-28 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210068909.5A Active CN114344301B (zh) 2019-10-22 2020-09-28 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型

Country Status (6)

Country Link
US (1) US20220251044A1 (zh)
EP (1) EP4049999A4 (zh)
JP (1) JP2022553706A (zh)
KR (1) KR20220088743A (zh)
CN (2) CN114344301B (zh)
WO (1) WO2021077994A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024227A (zh) * 2011-07-22 2014-09-03 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
CN104684897A (zh) * 2012-07-16 2015-06-03 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
WO2019030711A1 (en) * 2017-08-11 2019-02-14 Dr. Reddy’S Laboratories Limited POLYMORPHS AND CO-CRYSTALS OF ROXADUSTAT
CN109369525A (zh) * 2018-12-29 2019-02-22 安礼特（上海）医药科技有限公司 罗沙司它的新晶型及其制备方法
WO2019042485A1 (en) * 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN201641043301A (zh) 2016-12-19 2018-06-22
PL3679017T3 (pl) 2017-09-04 2022-01-17 Sandoz Ag Kokryształ doustnie dostępnego inhibitora hydroksylazy prolilowej hif
CN110218184B (zh) 2018-03-01 2022-09-27 广东东阳光药业有限公司 诺德司他共晶及其制备方法
CN111320583A (zh) 2018-12-14 2020-06-23 广东东阳光药业有限公司 诺德司他新晶型及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024227A (zh) * 2011-07-22 2014-09-03 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
CN104684897A (zh) * 2012-07-16 2015-06-03 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
WO2019030711A1 (en) * 2017-08-11 2019-02-14 Dr. Reddy’S Laboratories Limited POLYMORPHS AND CO-CRYSTALS OF ROXADUSTAT
WO2019042485A1 (en) * 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
CN109369525A (zh) * 2018-12-29 2019-02-22 安礼特（上海）医药科技有限公司 罗沙司它的新晶型及其制备方法

Also Published As

Publication number Publication date
WO2021077994A1 (zh) 2021-04-29
EP4049999A4 (en) 2023-04-19
US20220251044A1 (en) 2022-08-11
CN114344301A (zh) 2022-04-15
EP4049999A1 (en) 2022-08-31
CN114344301B (zh) 2023-06-23
JP2022553706A (ja) 2022-12-26
KR20220088743A (ko) 2022-06-28
CN113015722B (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
CN113242855B (zh) 他发米帝司的晶型及其制备方法和用途
CN110088088B (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
CN111344283B (zh) Arn-509的晶型及其制备方法和用途
CN114929671B (zh) 化合物i二盐酸盐的共晶及其制备方法和用途
CN111093668A (zh) Gsk1278863 的晶型及其制备方法和制药用途
CN111094290B (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
WO2021129465A1 (zh) 一种Resmetirom晶型及其制备方法和用途
EP3502105A1 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
WO2020177645A1 (zh) 一种Upadacitinib的晶型及其制备方法和用途
WO2020057622A1 (zh) 卡博替尼苹果酸盐晶型及其制备方法和用途
WO2020063939A1 (zh) 一种Upadacitinib的晶型及其制备方法和用途
CN114907325A (zh) Belumosudil甲磺酸盐的晶型及其制备方法和用途
CN114621212A (zh) Lanifibranor的晶型及其制备方法和用途
CN114621211A (zh) Lanifibranor的晶型及其制备方法和用途
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
CN110650960B (zh) Acalabrutinib的新晶型及其制备方法和用途
CN110621674B (zh) 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
CN113015722B (zh) 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型
WO2019134455A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
WO2022052822A1 (zh) Resmetirom的晶型及其制备方法和用途
CN114630668B (zh) 一种Aprocitentan晶型及其制备方法和用途
CN115073430A (zh) Belumosudil甲磺酸盐的晶型及其制备方法和用途
WO2019105359A1 (zh) Acalabrutinib的晶型及其制备方法和用途
WO2019149262A1 (zh) Sb-939的晶型及其制备方法和用途
CN112794854A (zh) Ribociclib的半琥珀酸盐晶型CSI及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant